• news.cision.com/
  • Genovis AB/
  • Genovis and GlycoT Therapeutics enter into cross-licensing agreements on novel antibody conjugation technology

Genovis and GlycoT Therapeutics enter into cross-licensing agreements on novel antibody conjugation technology

Report this content

Under the agreements, the combined proprietary technology platform will enable Genovis and GlycoT Therapeutics (“GlycoT”) to market, sell and further develop enzymatic workflows for the research and diagnostics markets as well as for therapeutic applications.

As part of the cross-licensing agreements, Genovis will license enzyme technology from GlycoT and at the same time out-license enzyme technology to GlycoT. The exchange of technology access enables both companies to offer a significantly improved enzyme driven workflow technology to increase the implementation of site-specific antibody conjugation to several application in research, diagnostics and biopharma markets.

Conjugation of molecules to antibodies are frequently used for a wide variety of applications within the life science industry. The need for stable, robust and site-specific conjugation technologies are continuously growing within basic research, diagnostics and pharma markets, including antibody-drug conjugate development. Conjugation to antibodies have traditionally been performed using chemical technologies that produce heterogenous conjugates that may reduce performance due to unwanted side reactions and often requires optimization for each antibody to be labeled. The use of specific enzymes for performing conjugation can effectively remove many of the concerns frequently observed with chemical conjugation. Combining GlycoT and Genovis technologies have the potential to significantly improve quality, reproducibility and productivity in the antibody labelling field.

“I am very pleased to be collaborating with GlycoT and combine the promising enzyme conjugation technology and expertise they have developed   with Genovis SmartEnzymesand our proven track record for enzyme driven workflows for the life science market. I am looking forward to broaden our product offering together with GlycoT and to further expand our customer base in biopharma, research and diagnostic markets with this new technology platform”, says Fredrik Olsson CEO Genovis.

“We at GlycoT are very excited for the opportunity to team up with Genovis for explorations in the areas of glycan-mediated site-selective labeling and conjugation of antibodies. The combination of our complementary technology and expertise will significantly expand the toolbox for the research community and will speed up the development of more efficient diagnostic and therapeutic methods”, says Lai-Xi Wang, President and Founder, GlycoT Therapeutics.

About GlycoT Therapeutics(www.glycot.com) GlycoT Therapeutics explores innovative chemoenzymatic glycoengineering as a platform technology for site-specific antibody labeling and conjugation. Current focus is to apply the glycoengineering technology for optimizing glycosylation of therapeutic antibodies and for producing homogeneous antibody-drug conjugates as improved therapeutics for the treatment of cancer, inflammation, and infectious diseases.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: +46 (0)70-276 46 56 fredrik.olsson@genovis.com

Genovis’business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.setel: +46 (0)8-463 83 00.


Documents & Links